Pathway Gets EU Marketing Approval for PAD Catheter

Pathway Medical Technologies received CE Marking for its Jetstream G2 NXT system and is developing plans to launch the catheter in Europe. The device, designed to remove artery-clogging plaque in the lower limbs, was cleared by the FDA in August. The minimally invasive device is indicated to treat peripheral arterial disease (PAD), a condition that affects more than 27 million people in Europe and North America, Pathway says in a statement.